塞里斯制药

最新新闻

• 评级变动
  Xeris Pharmaceuticals (XERS) Receives a Buy From H.C. Wainwright
  TipRanks · 2025/9/17
• 评级变动
  TR | OpenAI - 4o Maintains Xeris Pharmaceuticals(XERS.US) With Hold Rating, Raises Target Price to $7.5
  Market Newswire · 2025/8/12
• 评级变动
  H.C. Wainwright Initiates Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $10
  Market Newswire · 2025/8/12
• Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $12
  Market Newswire · 2026/9/29
• 评级变动
  Piper Sandler Maintains Xeris Pharmaceuticals(XERS.US) With Hold Rating, Maintains Target Price $8
  Market Newswire · 2026/9/10
• H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)
  TipRanks · 2026/9/22
• 评级变动
  Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $18
  Market Newswire · 2025/11/7
• 评级变动
  Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $11
  Market Newswire · 2025/8/8
• 评级变动
  Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $9
  Market Newswire · 2025/8/20
• 评级变动
  Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $18
  Market Newswire · 2025/10/29
• 评级变动
  Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $9
  Market Newswire · 2026/5/14
• Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $14
  Market Newswire · 2026/10/6
• 评级变动
  Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
  Market Newswire · 2026/7/1
• 评级变动
  Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $16
  Market Newswire · 2026/9/10
• 评级变动
  Piper Sandler Downgrades Xeris Pharmaceuticals(XERS.US) to Hold Rating, Raises Target Price to $8
  Market Newswire · 2025/11/7
• 评级变动
  Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $8
  Market Newswire · 2025/8/8
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Xeris Pharmaceuticals (XERS)
  TipRanks · 2026/3/3
• Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $12
  Market Newswire · 2026/8/20
• 评级变动
  Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $12
  Market Newswire · 2026/7/8
• H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $10
  Market Newswire · 2026/9/22
• 评级变动
  Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $7
  Market Newswire · 2025/6/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。